NCT07076823View on ClinicalTrials.gov

Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Colorectal CancerSGLT-2 Inhibitor
Interventions
DRUG

Canagliflozin

Low-dose cohort: 100 mg qd, taken before the first meal of the day. High-dose cohort: Starting dose of 100 mg qd for 1 week. If tolerated, the dose will escalate to 300 mg qd, taken before the first meal of the day.

Trial Locations (1)

610041

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER